News | December 14, 2025
Biocon Biologics strikes deal to sell its version of the eye drug Aflibercept worldwide
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
The inspection concluded with one minor observation in Form 483
The companies aim to expand treatment options for millions living with metabolic disorders
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Expands bioprocessing footprint across Asia
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
It's an acquisition that aims at forming one of the US's largest oncology trial networks
Subscribe To Our Newsletter & Stay Updated
